Printer Friendly

CELONOVA UNVEILS CATANIA CORONARY STENT WITH POLYZENE-Z.

CeloNova BioSciences, Inc., Atlanta, a developer of innovative medical devices, has announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F.

Corrado Tamburino, MD, president of the Italian Society of Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full Professor of Cardiology at the University of Catania is Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other stent systems."

The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The CAT" by cardiologists who have used the product, has completed CE Marking and is available for sale anywhere the CE Mark is accepted. Advantages include:

-- Early and complete vessel healing, as early as 30 days.

-- Patients can discontinue dual anti-platelet therapy after only one month.

-- Protection from stent thrombosis

-- The Polyzene(R)-F surface treatment is bacterial-resistant

"The FDA has cautioned physicians about a small but significant increased risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. Polyzene(R)-F seems to solicit a positive biological response that treats the stent as accepted part of the vessel. As a result, 'The CAT' patients have excellent outcomes and can be free from the medical complications and financial burden associated with indefinite anti-platelet therapy," stated Thomas A. Gordy, president and CEO.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline.

For more information, visit http://www.celonova.com or call 770/502-0304.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Article Type:Clinical report
Date:Mar 1, 2008
Words:382
Previous Article:VOLCANOE REPORTS FDA 510(K)OF ROTATIONAL CATHETER/FFR.
Next Article:BOSTON SCIENTIFIC ASSESSES OLIMUS-ELUTING STENTS REGISTRY.
Topics:


Related Articles
OLYMPIA PHASE I REGISTRY SHOWS EFFICACY OF TAXUS STENT.
ABBOTT ENROLLS FIRST PATIENT IN XIENCE STENT TRIAL.
ABBOTT REPORTS POSITIVE SUBSET RESULTS FOR XIENCE V.
CYPHER STENT OUTPERFORMS TAXUS STENT IN LONG CORONARY LESIONS.
ABBOTT'S XIENCE CORONARY STENT SUPERIOR TO TAXUS.
BOSTON SCIENTIFIC COMPLETES ENROLLMENT IN SYNTAX CLINICAL TRIAL.
BOSTON SCIENTIFIC ASSESSES OLIMUS-ELUTING STENTS REGISTRY.
MEDTRONIC'S NEW ENDEAVOR STENT APPROVED IN CANADA.
ABBOT SUBMITS XIENCE V ELUTING STENT FOR APPROVAL IN JAPAN.
FDA APPROVES ABBOTT'S XIENCE V DRUG ELUTING STENT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters